August 2012
-
Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana’s intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development… Read more . . .
-
A group comprised of Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium, and CDMO OXB, has announced the initiation of the Phase 1/2 Lenticlair 1 study of BI 3720931, an inhaled lentiviral vector-based gene therapy… Read more . . .
-
Texas-based Zeteo Biomedical has announced the launch of two new devices for intranasal delivery of dry powders: the CygnusMR multi-dose device and the CygnusSDX single dose disposable device. In 2022, the company announced the launch… Read more . . .
-
Kyorin Pharmaceutical is paying an undisclosed fee for the option to license Japanese development and marketing rights to Cyrano Therapeutics’ CYR intranasal theophylline for the treatment of loss of smell, the companies said. A Phase… Read more . . .
-
According to Kexing Biopharm, the FDA has approved the company’s IND for GB05 human interferon alpha-1b inhalation solution, which the company’s subsidiary Shenzhen Kexing plans to advance into clinical development for the treatment of lung… Read more . . .
-
The Coalition for Epidemic Preparedness Innovations (CEPI) is providing $5 million to inhaled RNA developer Ethris for development of spray-dried RNA vaccines for nasal delivery. Ethris said that it plans to focus initially on a… Read more . . .
-
AIM ImmunoTech has announced that it plans to move forward with a trial of intranasal Ampligen rintatolimod as an adjuvant to AstraZeneca’s FluMist intranasal flu vaccine for the prevention of avian flu. The company said… Read more . . .
-
According to ENA Respiratory, California-based non-profit organization Flu Lab is providing a $5 million investment to support a Phase 2 proof of concept study of the company’s INNA-051 intranasal dry powder TLR2/6 agonist for the treatment… Read more . . .
-
According to Cessatech, a positive notified body opinion has been issued under Article 117 of the Medical Devices Regulation for the company’s CT001 sufentanil / ketamine nasal spray. Cessatech says that it expects to submit… Read more . . .
-
California-based startup Miist Therapeutics, which calls itself “a physics-based developer of inhaled medicines,” announced that it has raised $7 million in seed funding and is developing 2 candidates: MST-01 for smoking cessation and MST-02 for… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.